Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday.
Biodexa製藥公司PLC（納斯達克：BDRX）股票週四交易下跌。
The company released patient updates on progression-free survival (PFS) and overall survival (OS) from the ongoing MAGIC-1 study of MTX110 in recurrent glioblastoma (rGBM), a form of adult brain cancer.
公司發佈了關於進行中的MAGIC-1研究中MTX110用於複發性膠質母細胞瘤（rGBM），一種成人腦癌形式的患者更新，涉及無進展生存期（PFS）和總體生存期（OS）。
The study evaluates the feasibility, safety, and efficacy of treating rGBM patients with MTX110.
該研究評估了用MTX110治療rGBM患者的可行性、安全性和有效性。
Also Read: Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday – Here's Why.
還閱讀：腫瘤焦點的納米級公司Biodexa製藥股票週四飆升——原因在這裏。
The company earlier reported that patients #1 and #2 in Cohort A achieved overall survival (OS) of 12 and 13 months, respectively.
公司早前報告，A組的1號和2號患者的總體生存期（OS）分別爲12個月和13個月。
The remaining two patients in Cohort A remain on follow-up.
A組中其餘兩名患者仍在隨訪中。
Patient #3 has achieved 13 months of OS to date, with six months of progression-free survival (PFS).
患者3號至今已達到13個月的OS，並獲得了6個月的無進展生存期（PFS）。
Patient #4 has not progressed and has achieved 12 months of PFS and 12 months of OS to date.
患者4號未病情惡化，目前已達到12個月的PFS和OS。
"The interim data from the MAGIC-G1 study has raised hopes that MTX110 could provide a new treatment option that offers real benefits in survival without the toxicity associated with traditional chemotherapy," the company says.
「MAGIC-G1研究的臨時數據提高了人們對MTX110可能提供新的治療選擇，不僅可以在生存上帶來真正的好處，而且沒有傳統化療所帶來的毒性。」公司表示。
MTX110 has been evaluated for Diffuse midline glioma (DMG), a rare but highly aggressive form of brain cancer that often affects children, in two Phase 1 trials.
MTX110已經被評估用於瀰漫性中線神經膠質瘤（DMG），這是一種罕見但高度侵襲性的腦癌形式，通常影響兒童，在兩項第1期試驗中。
A phase 1 study conducted by the University of California, San Francisco (UCSF) involved patients with DMG and reported a median overall survival of 26.1 months. This contrasts with the historical median survival of around 10 months for patients with DMG.
由加州大學舊金山分校（UCSF）進行的第1期研究涉及患有DMG的患者，並報告了26.1個月的中位總生存期。這與歷史上DMG患者約爲10個月的中位生存期形成對比。
In a separate phase 1 trial involving newly diagnosed DMG patients at Columbia University, MTX110 demonstrated, after only two infusions per patient, similarly encouraging results, improving median overall survival to 16 months.
在哥倫比亞大學進行的一項單獨的第1期試驗中，涉及新診斷的DMG患者，MTX110僅通過每位患者兩次輸注，顯示了類似鼓舞人心的結果，將中位總體生存期提高到16個月。
Price Action: BDRX stock is down 30.01% at $5.88 at the last check Thursday.
股價表現：BDRX股價在上週四最後一次檢查時下跌了30.01%，至5.88美元。
- FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
- FDA批准艾伯維公司的帕金森病治療藥物，預計明年將獲得醫保覆蓋。
譯文內容由第三人軟體翻譯。
